Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00687297 · ClinicalTrials.gov registry record · Phase 2

Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer

A Phase 2 study of Non-Small Cell Lung Cancer and Lung Cancer, sponsored by PrECOG.

Completed
Registry status
Phase 2
Development phase
162
Enrollment target
20
Study locations

NCT00687297: Completed Phase 2 study of Non-Small Cell Lung Cancer and Lung Cancer, sponsored by PrECOG.

NCT00687297 is a Phase 2 study of Non-Small Cell Lung Cancer and Lung Cancer that has completed, run by PrECOG. The registered enrollment target is 162 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00687297, a Phase 2 study of Non-Small Cell Lung Cancer and Lung Cancer, has completed, sponsored by PrECOG.

COMPLETED
Registry status
Phase 2
Development phase
162 participants
Enrollment target
20
Study locations

Study Summary

It has been shown in previous studies that the ability to treat lung cancer could be significantly improved by not only targeting the tumor cells directly with chemotherapy, but also by cutting off the blood supply to the cancer cells. Blood vessels that supply the tumor are formed through a process called angiogenesis. Vandetanib is an investigational drug that acts by producing what is called an anti-angiogenic effect. An Anti-angiogenic effect is able to inhibit the development of new blood vessels required by tumors to survive by blocking the growth factors needed to form new blood vessels. The purpose of this study is to determine if the addition of vandetanib to a standard chemotherapy regimen will slow or stop the growth of the cancer for a longer period of time compared to the time period generally gained from the use of standard chemotherapy alone

Primary Outcome

Time from randomization (prior to induction) to first evidence of disease progression or death without progression. Participants alive without progression were censored at the date of last disease evaluation.

Conditions Studied

Non-Small Cell Lung Cancer Lung Cancer

Interventions

  • DRUG Carboplatin
  • DRUG Placebo
  • DRUG Docetaxel
  • DRUG vandetanib induction
  • DRUG Vandetanib maintenance

Study Locations (20)

Pennsylvania

  • Abington Memorial Hospital - Abington
  • Hematology & Oncology of NEPA - Dunmore
  • Lancaster General Hospital - Lancaster
  • Central PA Hematology & Medical Oncology Associaties - Lemoyne
  • University of Pennsylvania - Philadelphia

New Jersey

  • Ocean Medical Center - Brick
  • Morristown Memorial Hospital - Morristown
  • Cancer Institute of New Jersey - New Brunswick
  • Riverview Medical Center - Red Bank

Florida

  • Boca Raton Community Hospital - Boca Raton
  • Lakeland Regional Cancer Center - Lakeland

Michigan

  • St. Joseph Mercy Hospital- Ann Arbor - Ann Arbor
  • West Michigan Cancer Center - Kalamazoo

Illinois

  • SwedishAmerican Hospital - Rockford

Kansas

  • Cancer Center of Kansas - Wichita

Louisiana

  • Ochsner Clinic - New Orleans

Maryland

  • Greater Baltimore Medical Center - Baltimore

Trial Details

FieldValue
Enrollment Target 162 participants
Start Date 2008-04
Est. Completion 2011-04
Phase Phase 2
PrECOG

17 total trials

What the finished NCT00687297 record still lists

NCT00687297 is an interventional study that assigns participants to a tested intervention. The registered 162 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (75% lower).

The record links to 2 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.

NCT00687297 names 20 study sites across 11 states, led by Pennsylvania, New Jersey, Florida.

Frequently Asked Questions

What is clinical trial NCT00687297 about?

NCT00687297 is a clinical study titled "Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer". It has been shown in previous studies that the ability to treat lung cancer could be significantly improved by not only targeting the tumor cells directly with chemotherapy, but also by cutting off the blood supply to the cancer cells. Blood vessels that supply the tumor are formed through a process...

What is the current status of trial NCT00687297?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 162 participants. The study started on 2008-04. Estimated completion is 2011-04.

What conditions does trial NCT00687297 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Lung Cancer.

What interventions are being tested in trial NCT00687297?

The interventions under investigation include: Carboplatin (DRUG), Placebo (DRUG), Docetaxel (DRUG), vandetanib induction (DRUG), Vandetanib maintenance (DRUG).

Who is sponsoring clinical trial NCT00687297?

This trial is sponsored by PrECOG, which has 17 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00687297 being conducted?

This trial has 20 study locations across Florida, Illinois, Kansas, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00687297's enrollment target sits among peer trials

162 189th of 454 higher than 264 of 454 other Non-Small Cell Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02347111 · 162 participants · Phase 4

    Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation

  • NCT02610426 · 162 participants

    Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer

  • NCT05040711 · 162 participants · NA

    mHealth Mindfulness With Patients With Serious Illness and Their Caregivers

  • NCT05514717 · 162 participants · Phase 1

    A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00687297, the US trial registry maintained by the National Library of Medicine. NCT00687297 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.